Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Key Takeaways More people with type 1 diabetes are severely obese and using GLP-1 drugs for weight lossExperts are concerned ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.